

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 6

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following reference which is listed on the attached Form PTO-1449 (**Exhibit A**) and a copy of which is attached hereto as **Exhibit 1**:

1. U.S. Serial No. 09/764,710, filed January 17, 2001,  
Michael Konkel, et al. (**Exhibit 1**).

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following disclosures which are listed on the attached Form PTO-1449 (**Exhibit A**) and which were previously submitted or cited in connection with the prosecution of U.S. Serial No. 09/764,710 from which the subject application claims priority under 35 U.S.C. §120. According to 37 C.F.R. § 1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement.

1. PCT International Application No. WO 01/05765, published January 25, 2001;
2. PCT International Publication No. WO 99/57131, published November 11, 1999;
3. Snowball, R.K. et al. Investigation of the role of  $\alpha_{1A}$ - and  $\alpha_{1D}$ - adrenoceptors in the control of the "micturition reflex" in the anaesthetized male rat. British Journal of Pharmacology, Proceedings of the British Pharmacology

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 7

Society Meeting January 5-7, 2000, Abstract 35P;

4. U.S. Patent No. 3,398,151, issued August 20, 1968, Wu;
5. U.S. Patent No. 3,558,777, issued January 26, 1971, Wu;
6. U.S. Patent No. 4,988,700, issued January 29, 1991, Traber et al.;
7. U.S. Patent No. 5,070,102, issued December 3, 1991, Traber et al.;
8. U.S. Patent No. 5,096,908, issued March 17, 1992, Gidda and Schaus;
9. U.S. Patent No. 5,155,128, issued October 13, 1992, Traber et al.;
10. U.S. Patent No. 5,200,410, issued April 6, 1993, Traber et al.;
11. U.S. Patent No. 5,258,379, issued November 2, 1993, Gidda and Schaus;
12. U.S. Patent No. 5,294,619, issued March 15, 1994, Nagel;
13. European Patent Application No. 0 372 776, published June 13, 1990, Nagel;
14. European Patent Application No. 0 395 312, published October 31, 1990, Cliffe;
15. European Patent Application No. 0 447 345, published September 18, 1991, Orjales-Venero and Rodes-Solanes;

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 8


16. European Patent Office No. 0 455 510, published November 6, 1991, Gidda and Schaus;
17. German Patent DE 40 39 631, published June 17, 1992;
18. Goetz, A.S. et al., BMY 7378 is a selective antagonist of the D subtype of  $\alpha_1$ -adrenoceptors. Eur. J. Pharmacol. (1995) 272: R5-R6;
19. Lopez-Rodriguez et al., 1-[ (4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylen-2,5-pyrrolidinediones as 5-HT<sub>1A</sub> receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT<sub>1A</sub> affinity/selectivity. Bioorganic & Medicinal Chemistry Letters (1998) 8: 581-586;
20. Saussy, D.L. Jr. et al., Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J. Pharmacol. Exp. Ther. (1996) 278: 136-144; and
21. Wu, Y.-H. et al., Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. J. Med. Chem. (1969) 12: 876-881.

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 9

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed fee of \$1,060.00 for filing the subject application is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

  
John P. White  
John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212)278-0400

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>								<b>Atty. Docket No. 1795/54927-AA-PCT- US/JPW/ANX</b>	<b>Serial No. Not Yet Known</b>
<b>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</b>										<b>Applicants Michael Konkel, et al.</b>	
										<b>Filing Date Herewith</b>	<b>Group Art Unit Not Yet Known</b>

**U.S. PATENT DOCUMENTS**

<b>Examiner Initial</b>		<b>Document Number</b>							<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>
	US	3	3	9	8	1	5	1	08/20/68	Wu			
	US	3	5	5	8	7	7	7	01/26/71	Wu			
	US	4	9	8	8	7	0	0	01/29/01	Traber, et al.			
	US	5	0	7	0	1	0	2	12/3/91	Traber, et al.			

**FOREIGN PATENT DOCUMENTS**

		<b>Document Number</b>							<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
													<b>Yes</b>	
		9	9	5	7	1	3	1	November 11, 1999	PCT				No
		0	3	7	2	7	7	6	June 13, 1990	EPO				
		0	3	9	5	3	1	2	October 31, 1990	EPO				
		0	4	4	7	3	4	5	September 18, 1991	EPO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Snowball, R.K. et al. Investigation of the role of $\alpha_{1A}$ - and $\alpha_{1D}$ - adrenoceptors in the control of the "micturition reflex" in the anaesthetized male rat. British Journal of Pharmacology, Proceedings of the British Pharmacology Society Meeting January 5-7, 2000, Abstract 35P;
	Goetz, A.S. et al., BMY 7378 is a selective antagonist of the D subtype of $\alpha_1$ -adrenoceptors. Eur. J. Pharmacol. (1995) 272: R5-R6;
	Lopez-Rodriguez et al., 1-[ $\omega$ (4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylen-2,5-pyrrolidinediones as 5-HT <sub>1A</sub> receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT <sub>1A</sub> affinity/selectivity. Bioorganic & Medicinal Chemistry Letters (1998) 8: 581-586;

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Atty. Docket No. 1795/54927-AA-PCT- US/JPW/ANX</b>	<b>Serial No. Not Yet Known</b>
<b>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</b>		<b>Applicants Michael Konkel, et al.</b>		
		<b>Filing Date Herewith</b>	<b>Group Art Unit Not Yet Known</b>	

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
US		5 0 9 6 9 0 8	3/17/92	Gidda and Schaus			
US		5 1 5 5 1 2 8	10/13/ 92	Traber, et al.			
US		5 2 0 0 4 1 0	4/6/93	Traber, et al.			
US		5 2 5 8 3 7 9	11/2/ 93	Gidda and Schaus			
US		5 2 9 4 6 1 9	3/15/94	Nagel			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		0 4 5 5 5 1 0	Nov. 6, 1991	EPO				
		4 0 3 9 6 3 1	June 17, 1992	Germany				
		0 1 5 6 7 6 5	January 25, 2001	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Saussay, D.L. Jr. et al., Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J. Pharmacol. Exp. Ther. (1996) 278: 136-144;
	Wu, Y.-H. et al., Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. J. Med. Chem. (1969) 12: 876-881;
	U.S. Serial No. 09/764,710, filed January 17, 2001, Michael Konkel, et al. (Exhibit 1)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.